Drug intelligence / Profile preview

TORL-3600

Development stage: Phase 1
Lead developer: TORL BioTherapeutics
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TORL-3600 is an antibody-drug conjugate (ADC) under development by TORL Biotherapeutics for the treatment of advanced solid tumors, including colorectal cancer, gastric cancer, and pancreatic cancer. The drug targets cadherin 17 (CDH17), a cell adhesion molecule implicated in tumor growth and metastasis. By binding to CDH17 on tumor cells, the ADC delivers a cytotoxic payload that disrupts microtubule function (tubulin inhibition), leading to cell death. As of April 2025, TORL-3600 is in Phase 1 clinical trials for advanced cancers and colorectal cancer[1][3][4][6].

Targets

CDH17 (Cadherin-17)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on TORL-3600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TORL-3600.

Explore the full profile